A detailed history of Israel Englander (Millennium Management LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 129,813 shares of CPRX stock, worth $2.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129,813
Previous 104,536 24.18%
Holding current value
$2.58 Million
Previous $1.67 Million 20.65%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $371,066 - $427,686
25,277 Added 24.18%
129,813 $2.01 Million
Q1 2024

May 15, 2024

SELL
$13.18 - $17.11 $977,758 - $1.27 Million
-74,185 Reduced 41.51%
104,536 $1.67 Million
Q4 2023

Feb 14, 2024

SELL
$11.78 - $17.29 $1.61 Million - $2.36 Million
-136,340 Reduced 43.27%
178,721 $3 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $12 Million - $18.8 Million
-1,040,034 Reduced 76.75%
315,061 $4.23 Million
Q1 2023

May 15, 2023

SELL
$14.34 - $21.05 $13.7 Million - $20.2 Million
-958,571 Reduced 41.43%
1,355,095 $22.5 Million
Q4 2022

Feb 14, 2023

BUY
$12.25 - $19.5 $10.7 Million - $17 Million
873,308 Added 60.63%
2,313,666 $43 Million
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $9.06 Million - $19.9 Million
-1,283,537 Reduced 47.12%
1,440,358 $18.5 Million
Q2 2022

Aug 15, 2022

BUY
$6.23 - $8.57 $9.72 Million - $13.4 Million
1,560,086 Added 134.05%
2,723,895 $19.1 Million
Q1 2022

May 16, 2022

BUY
$5.31 - $8.31 $4.95 Million - $7.75 Million
932,377 Added 402.87%
1,163,809 $9.65 Million
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.45 $923,451 - $1.32 Million
177,246 Added 327.11%
231,432 $1.57 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $6.04 $1.19 Million - $1.48 Million
-245,187 Reduced 81.9%
54,186 $287,000
Q2 2021

Aug 16, 2021

SELL
$4.29 - $6.05 $1.34 Million - $1.89 Million
-312,637 Reduced 51.08%
299,373 $1.72 Million
Q1 2021

May 17, 2021

BUY
$3.45 - $4.69 $603,487 - $820,393
174,924 Added 40.02%
612,010 $2.82 Million
Q4 2020

Feb 16, 2021

BUY
$2.97 - $3.83 $1.21 Million - $1.56 Million
406,817 Added 1344.01%
437,086 $1.46 Million
Q3 2020

Nov 16, 2020

SELL
$2.97 - $5.08 $697,308 - $1.19 Million
-234,784 Reduced 88.58%
30,269 $90,000
Q2 2020

Aug 14, 2020

SELL
$3.48 - $5.05 $1.98 Million - $2.87 Million
-567,948 Reduced 68.18%
265,053 $1.23 Million
Q1 2020

May 14, 2020

BUY
$2.61 - $5.21 $2.09 Million - $4.17 Million
801,306 Added 2528.18%
833,001 $3.21 Million
Q4 2019

Feb 14, 2020

SELL
$3.67 - $5.7 $162,034 - $251,660
-44,151 Reduced 58.21%
31,695 $119,000
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $295,040 - $563,535
75,846 New
75,846 $402,000
Q4 2018

Feb 14, 2019

SELL
$1.92 - $3.62 $257,316 - $485,148
-134,019 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$2.81 - $3.78 $4.15 Million - $5.58 Million
-1,476,157 Reduced 91.68%
134,019 $507,000
Q2 2018

Aug 14, 2018

BUY
$2.26 - $3.84 $515,094 - $875,205
227,918 Added 16.49%
1,610,176 $5.02 Million
Q1 2018

May 15, 2018

SELL
$2.39 - $4.01 $1.64 Million - $2.75 Million
-684,622 Reduced 33.12%
1,382,258 $3.3 Million
Q4 2017

Feb 14, 2018

BUY
$2.51 - $4.4 $5.19 Million - $9.09 Million
2,066,880
2,066,880 $8.08 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.04B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.